TCWA
QNCX icon

Ten Capital Wealth Advisors’s Quince Therapeutics QNCX Stock Holding History

Ten Capital Wealth Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$254 – 436
2023
Q1 		$254 Hold
1
– – ﹤0.01% 530
2022
Q4 		$104 Hold
1
– – ﹤0.01% 574
2022
Q3 		$0 Hold
1
– – ﹤0.01% 612
2022
Q2 		$0 Hold
1
– – ﹤0.01% 512
2022
Q1 		$1K Hold
1
– – ﹤0.01% 456
2021
Q4 		$2K Buy
+1
New +$6.1K ﹤0.01% 424

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KAM
Knightsbridge Asset Management Newport Beach, California $743M AUM 28.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ten Capital Wealth Advisors's QNCX Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Quince Therapeutics (QNCX) in Q2 2023, closing a stake of 1 share — an estimated $254 sold.

Ten Capital Wealth Advisors first reported a position in QNCX in Q4 2021 and held it in 6 quarters. The position peaked at $2K in Q4 2021. 38 funds tracked by Wall St. Rank hold QNCX as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Quince Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 1 Quince Therapeutics share in Q2 2023, an estimated $254.
  • Ten Capital Wealth Advisors first reported a position in Quince Therapeutics in Q4 2021 and held it in 6 quarters.
  • Ten Capital Wealth Advisors's Quince Therapeutics position peaked at $2K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.